SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) announced today that Charles Butler, the companys vice president of investor relations and corporate communications, will present at the JMP Securities 7^th Annual Healthcare Conference at 9:30 a.m. EDT / 6:30 a.m. PDT on Friday, July 13, 2012, in New York. During the presentation, Mr. Butler will discuss the companys development program and plans for cabozantinib, and review the most recent publicly available data for the compound. He will also provide a general business update.

The presentation will be webcast and may be accessed via the Event Calendar page under Investors at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and
Corporate Communications
cbutler@exelixis.com

Source: Exelixis, Inc.